Request Demo

Last update 24 Mar 2025

Fentanyl

Last update 24 Mar 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryFentanyl is a synthetic opioid that is highly effective in the management of severe pain, especially in cancer patients. It exerts its analgesic effects by binding to opioid receptors in the central nervous system. Fentanyl is available in various formulations, including transdermal patches, lozenges, and injectable solutions. However, due to its potency, fentanyl carries a high risk of addiction, respiratory depression, and overdose. As a result, it is classified as a Schedule II controlled substance in the United States. Ongoing research is focused on developing safer and more effective delivery methods for fentanyl, such as abuse-deterrent formulations and novel routes of administration.

Drug Type

Small molecule drug

Synonyms

AeroLEF, Fentany Transdermal System, Fentanyl (JAN/USP/INN)

+ [38]

Target

Opioid receptors

Action

agonists

Mechanism

Opioid receptors agonists(Opioid receptors agonists)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

Cancer PainChronic PainPain

Inactive Indication

Acute PainAdvanced cancerBreakthrough Pain+ [12]

Originator Organization

Janssen Global Services LLC

Active Organization

Zhaoke Pharmaceutical (Guangzhou) Ltd.

Janssen Pharmaceutica NVJanssen Pharmaceutical KK

+ [4]

Inactive Organization

Janssen Pharmaceuticals, Inc.Janssen Research & Development LLC

INSYS Therapeutics, Inc.

+ [3]

Drug Highest PhaseApproved

First Approval Date

United States (07 Aug 1990),

HypoventilationPain, Postoperative

Regulation-

Structure/Sequence

Molecular FormulaC22H28N2O

InChIKeyPJMPHNIQZUBGLI-UHFFFAOYSA-N

CAS Registry437-38-7

1,254

Clinical Trials associated with Fentanyl

NCT06793358

/ Not yet recruitingPhase 4IIT

Use of Remimazolam and Fentanyl for Procedural Sedation in Patients Undergoing Dental Extraction

The goal of this clinical trial is to learn if a combination of the two established sedation drugs remimazolam and fentanyl, can put the subject to sleep during a scheduled extraction procedure. The combined use of these drugs has been used in other studies involving IV sedation when the procedure is scheduled for 30 minutes or less. However, the combined use of the IV sedation drugs has not been used in a dental extraction procedure before.
The main questions it aims to answer are:
1. Can the combined drugs effectively put the patient to sleep during the procedure
2. How quickly will they come out of the sedation after the procedure
Participants will:
1. Receive the combined drugs during a scheduled extraction procedure anticipated to take less than 30 minutes
2. Answer survey questions related to their study experience after the extraction visit (in person) and again about 24 hours after the visit (by telephone).

Start Date30 Mar 2025

Sponsor / Collaborator

Indiana University

[+1]

NCT06799442

/ Not yet recruitingPhase 2/3IIT

Dexmedetomidine Versus Fentanyl As Adjuvants to Erector Spinae Plane Block for Postoperative Analgesia Following Simple Nephrectomy: a Randomized Clinical Trial

The aim of this clinical trial is to compare the time to first analgesic request between dexmedetomidine and fentanyl as adjuvants in erector spinae plane block in patients undergoing simple nephrectomy .
• Secondary outcome Pain scores; Numerical Rating Scale (NRS) at rest and when coughing [at 1, 2, 4, 8, 16 and 24 hours postoperatively.] The total opiod dose in the first 24 hours postoperatively. Duration of analgesia is defined as duration between block administration and time of first analgesic request.
Any adverse effects related to anesthesia or the technique. Incidence of Postoperative nausea & vomiting . Block related complication during and after block procedure till 24hours postoperatively (local anesthetic systemic toxicity, pneumothorax and vascular puncture during block procedure).
Intraoperative haemodynamics parameters MAP ,HR , co2 and SP O2 . Postoperative haemodynamics parameters MAP , HR and SP O2 [at 1, 2, 4, 8, 16 and 24 hours postoperatively. ]

Start Date01 Mar 2025

Sponsor / Collaborator

Assiut University

NCT06784180

/ Not yet recruitingPhase 4IIT

Intrathecal Hydromorphone vs Intrathecal Morphine to Treat Post Cesarean Pain in Patients With Opioid Use Disorder Taking Buprenorphine

This is a single center, double-blind, randomized trial to compare the effects of intrathecal hydromorphone versus intrathecal morphine to treat post cesarean pain in patients with OUD taking buprenorphine. Inclusion criteria include American Society of Anesthesiologists (ASA) Physical Status II or III presenting for cesarean delivery to be done under spinal anesthesia, who have a diagnosis of OUD and are taking buprenorphine. Exclusion criteria include contraindication to spinal anesthesia, allergy/intolerance to acetaminophen or ibuprofen and laboring patients who have an epidural that will be used for anesthesia for cesarean delivery. Potential subjects will be approached about participating in the study at either their preop anesthesia visit or on the day of surgery after surgical and anesthesia consent has been obtained. Enrolled patients will be randomly allocated to receive either 200 mcg of intrathecal morphine or 100 mcg of intrathecal hydromorphone (study opioid medication). Intraoperatively, with the patient in a sitting position a spinal block will be performed with administration of 0.75% bupivacaine in 8.25% dextrose, 15 mcg fentanyl and the study opioid medication. Supplemental intraoperative analgesia/anxiolysis will be administered at the discretion of the anesthesia care team. Ultrasound-guided transversus abdominis plane blocks will be performed bilaterally at the end of the procedure with 10mL liposomal bupivacaine mixed with 10mL 0.25% bupivacaine injected on each side. Post-cesarean multimodal pain regimen will include scheduled acetaminophen 650mg every 6 hours and scheduled ibuprofen 600mg every 6 hours. Oxycodone will be ordered for breakthrough pain, starting at 5mg every 6 hours as needed. Escalation of as needed pain medication will be at the discretion of the anesthesia team. The patient will be followed for the following 36 hours postoperatively. The primary outcome is the patient's pain score with movement at 12 hours. Secondary outcomes include pain scores at rest and with movement at 6 and 24 hours, satisfaction with anesthesia, time to first opioid use, total opioid consumption in 24 and 36 hours, subjective rating of nausea and pruritis over first 24 hours , treatment for nausea or pruritis in 24 and 36 hours, Obstetric Quality of Recovery 10 (ObsQoR10) score, and Global Health Numeric Rating Scale (NRS) score.

Start Date01 Mar 2025

Sponsor / Collaborator

The University of North Carolina at Chapel Hill

100 Clinical Results associated with Fentanyl

100 Translational Medicine associated with Fentanyl

100 Patents (Medical) associated with Fentanyl

30,141

Literatures (Medical) associated with Fentanyl

01 Jun 2025·Intensive and Critical Care Nursing

The comparison of pupillometry to standard clinical practice for pain and preemptive analgesia before endotracheal suctioning: A randomized controlled trial

Article

Author: Perez-Francisco, Ines ; Vallejo-De-la-Cueva, Ana ; López-de-Audícana-Jimenez-de-Aberasturi, Yolanda ; Bermudez-Ampudia, Cristina ; Parraza-Diez, Naiara ; Bengoetxea-Ibarrondo, Miren Begoña

BACKGROUND:

Pain during endotracheal aspiration (ETA) is frequent in critically ill patients. Managing pre-emptive analgesia before procedures remains a crucial aspect of care. We compared pupillometry to standard clinical practice for assessing preemptive-analgesia administration and pain before ETA according to Behavioural Pain Scale (BPS), the Behavioural Pain Indicator Scale (ESCID), and the Pupillary Dilation Reflex (PDR).

TRIAL DESIGN:

A multicentre parallel-group, controlled trial with balanced (1:1) randomization.

METHODS:

Sedated, mechanically ventilated patients aged ≥ 18 with baseline BPS = 3, ESCID = 1, and RASS scores between -1 and -4 were included.

CONTROL GROUP:

preemptive-analgesia was administered according to nurse criteria. In the experimental group, preemptive analgesia was administered in patients with PDR ≥ 11.5 % after a 20 mA stimulus measured using AlgiScan®. The preemptive analgesia was fentanyl one µg/kg iv bolus. We used the Chi-square statistic to compare post-intervention pain according to BPS, ESCID, and PDR pain values. A multivariate logistic regression study adjusting for sex, BIS, RASS, APACHE II, remifentanil, and preemptive analgesia was conducted.

RESULTS:

Ninety-two patients were studied, 51 in control groups and 41 in intervention groups. Pain incidence was lower in the experimental group. Significantly, 43.9 % of patients in the experimental group were prescribed preemptive analgesia before ETA compared to 19.6 % in the control group (p = 0.03). Multivariate analysis showed significant reductions in pain in the group that received preemptive-analgesia before ETA guided by pupillometry across BPS [OR = 0.34 (95 % CI: 0.12-0.99), p = 0.048], ESCID [OR = 0.29 (95 % CI: 0.09-0.88), p = 0.030] and PDR [OR = 0.27 (95 % IC: 0.08-0.86), p = 0.027] compared to standard clinical practice.

CONCLUSIONS:

Preemptive analgesia monitored with pupillometry group had a lower percentage of patients with pain than those who received analgesia based on standard clinical practice. This effect was independent of the sex, patient severity, BIS score, remifentanil use, or preemptive- analgesia.

IMPLICATIONS FOR CLINICAL PRACTICE:

The requirement for preemptive analgesia before aspiration, evaluated through routine clinical practice, was lower than detected by pupillometric monitoring of patients. The use of pupillometry to monitor preemptive analgesia reduced pain after secretion aspiration. Pupillometry would be an effective tool to individualize the need for preemptive analgesia before potentially painful interventions, applicable to all patients regardless of sex, severity, or sedation level.

01 Jun 2025·Analytical science advances

Development and Validation of a Gas Chromatography‐Mass Spectrometry Method for the Determination of Fentanyl and Butyryl Fentanyl in Oral Fluid

Article

Author: Anzillotti, Luca ; Cecchi, Rossana ; Camedda, Nicola ; Dagoli, Sara

ABSTRACT:

Synthetic opioids are lab‐synthesized substances that target the brain's opioid receptors, offering analgesic and sedative effects. Amongst them, fentanyl is one of the most widely used to intervene in chronic pain in moderate to severe cancer situations. Butyryl fentanyl (BF) is a novel synthetic opioid whose use is growing. Its potency is seven times that of morphine and, unlike fentanyl, BF can only be obtained through illegal sources. Fentanyl and its analogues are related to harmful intoxications and an increase in opioid‐related mortality in many countries, such as in the United States and Europe in recent years. This work developed and validated an effective and sensitive method based on solid‐phase extraction followed by gas chromatography‐mass spectrometry (GC‐MS) for the determination of fentanyl and BF in oral fluid samples. To the best of our knowledge, it is the first successful attempt to quantify these analytes using GC‐MS with a limit of quantification (LOQ) of 1 ng/mL in OF. Intra‐day and inter‐day percentage coefficient of variation were found within 1%–3% and 1%–14%, respectively, while accuracy ranged from 92% to 102% at four concentration levels (lower LOQ [LLOQ], 3, 20, 40 ng/mL) in accordance with the established criteria. The absolute recovery values were in the range of 80.0%–100.0%. The method was linear for all analytes, with quadratic regression of calibration curves always higher than 0.99. The validated method demonstrated its great potential to detect and quantify fentanyl and its analogue in OF and it can be useful not only in forensic investigations of addiction histories but also in epidemiological studies on the spread of fentanyl and BF among workers and/or drivers.

01 Jun 2025·BIOMATERIALS

Janus LAAM-loaded electrospun fibrous buccal films for treating opioid use disorder

Article

Author: Puetzer, Jennifer L ; Xu, Qingguo ; Moeller, F Gerard ; Lu, Xiuling ; Pangeni, Rudra ; Chow, Woon N ; Pearcy, Adam ; Banks, Matthew L ; Halquist, Matthew S ; Zhao, Long ; Sudarjat, Hadi ; Arriaga, Michelle ; Ingabire, Diane ; Meng, Tuo ; Qin, Chaolong ; O'Keeffe, Charles ; Moothedathu Raynold, Aji Alex

The opioid crisis has claimed approximately one million lives in the United States since 1999, underscoring a significant public health concern. This surge in opioid use disorder (OUD) fatalities necessitates improved therapeutic options. Current OUD therapies often require daily clinical visits, leading to poor patient compliance and high costs to the health systems. Levo-alpha-acetylmethadol (LAAM) is a long-lasting OUD drug, and the thrice-weekly oral LAAM solution can offer better patient compliance compared to the traditional daily methadone therapies. However, LAAM is FDA-approved but withdrawn from the market. As part of the NIH HEAL Initiative, we aim to reintroduce LAAM back to the market to improve OUD therapeutic options by developing a novel Janus LAAM-loaded fibrous buccal film (LFBF) formulation made of a drug-containing electrospun fibrous layer and a backing layer. The buccal administration of LFBF exhibited superior transmucosal delivery of LAAM to systemic circulation with a nearly 4-fold higher drug bioavailability than the conventional oral LAAM solution in rabbits. Furthermore, upon buccal administration in an opioid-dependent rat model, the LFBF significantly decreased fentanyl choice in the fentanyl-dependent rats, while the conventional oral LAAM solution did not at the same dose. Both the buccal film and oral solution of LAAM reduced somatic withdrawal signs in the experimental animals. These findings highlight the buccal delivery of LAAM using electrospun fibers as a promising strategy with improved drug bioavailability. Furthermore, it sheds light on future clinical applications aiming for enhanced treatment outcomes in the battle against the current opioid crisis.

367

News (Medical) associated with Fentanyl

17 Mar 2025

·www.drugs.com

2015 to 2023 Saw Increase in Pediatric Nonfatal Fentanyl Exposures

MONDAY, March 17, 2025 -- From 2015 to 2023, there was an increase in the number of pediatric nonfatal fentanyl exposures reported to poison centers, according to a study published online March 7 in The American Journal of Drug and Alcohol Abuse . Joseph J. Palamar, M.P.H., Ph.D., from the NYU Grossman School of Medicine in New York City, and colleagues conducted a repeated cross-sectional study to examine characteristics of pediatric nonfatal fentanyl exposures reported to poison centers in 49 states from 2015 to 2023. The authors further examined the association of these characteristics with major outcomes. A total of 3,009 nonfatal pediatric exposures were reported to poison centers: 58.9 and 41.1 percent among those aged 13 to 19 and 0 to 12, respectively. The researchers found that from 2015 to 2023, there was an increase in the number of exposures from 69 to 893 (1,194.2 percent increase). Exposures increased by 924.3 and 1,506.3 percent among those aged 0 to 12 and 13 to 19, respectively. The most prevalent route of administration was ingestion-only use (76.9 and 54.1 percent in those aged 0 to 12 and 13 to 19, respectively). From 2015 to 2023, the prevalence of ingestion-only use increased from 44.1 to 67.9 percent of exposures. Most patients aged 0 to 12 years were exposed unintentionally (81.7 percent versus 1.0 percent among those aged 13 to 19 years), while most aged 13 to 19 misused or abused fentanyl (65.7 versus 1.8 percent). Forty-one percent of exposures resulted in a major (life-threatening) event. "Parents and others, too, need to be careful to not leave fentanyl, whether licit or illicit, out in the open around unsupervised children," Palamar said in a statement. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

14 Mar 2025

·www.echemi.com

5 Key Updates on China's Fentanyl Control Amid US Tariffs

On February 1st, the United States announced a 10% tariff on products imported from China, citing concerns over the fentanyl crisis. In response, a spokesperson from the Ministry of Public Security emphasized that China maintains one of the strictest drug control policies in the world. As a signatory to the three UN drug control conventions, China has consistently upheld its international obligations and actively collaborates with countries, including the US, on drug enforcement efforts. In 2019, China took a humanitarian step by becoming the first country to classify all fentanyl-related substances under stringent controls, responding to US requests. Since this classification, China has not received reports of these substances being seized in the US. On March 12th, the National Medical Products Administration (NMPA) shared insights regarding China's management of fentanyl substances through a recently released white paper. The spokesperson addressed concerns about the production and export of fentanyl-related pharmaceuticals. Currently, four fentanyl-related drugs are approved for clinical use in China: fentanyl, sufentanil, remifentanil, and alfentanil. Three companies have been authorized to produce raw materials, while five are permitted to manufacture formulations. In 2024, China produced 100 kilograms of fentanyl raw materials, primarily for domestic medical use and export, with only 12.3 kilograms exported to countries like South Korea, Vietnam, and the Philippines. Notably, China has never exported fentanyl products to North America. All fentanyl-related drugs in China are classified as controlled narcotics, subjected to stringent regulations. The production and distribution of these drugs are closely monitored, with specific companies designated for manufacturing and fixed sales channels established. Export controls require permits, and international verification ensures the legality of trade before issuing export licenses. The NMPA will continue to enhance the supervision of fentanyl-related drug production and strictly regulate exports to prevent illegal channels and misuse, ensuring that medical needs are met responsibly.

Drug Approval

13 Mar 2025

·www.globenewswire.com

Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform

Raanana, Israel, March 13, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, previously announced the initiation of preclinical studies for intranasal Naloxone, a life-saving opioid overdose treatment. As previously announced, the study will be conducted in collaboration with Professor Fabio Sonvico, Associate Professor at the Department of Food and Drug of the University of Parma (Italy) a leading expert in the development of intranasal and pulmonary drug delivery solutions and a member of the Company's Scientific Advisory Board. These preclinical studies mark a step forward in evaluating Polyrizon's Trap and Target™ (T&T) platform for the intranasal administration of Naloxone, an opioid antagonist designed to rapidly reverse opioid overdose. These studies will assess key parameters, such as drug loading capacity, release kinetics, nasal deposition and stability, laying the groundwork for further safety and efficacy testing in preclinical and clinical studies. "The opioid crisis continues to be a global public health emergency and improving Naloxone administration is essential for saving lives," said Tomer Izraeli CEO of Polyrizon. "Our proprietary T&T platform is designed to optimize drug delivery, and we believe it holds the potential to enhance intranasal Naloxone by offering higher bioavailability for increased drug effectiveness and optimized drug release profiles that ensure rapid opioid reversal when every second counts. These advantages could make a critical difference in emergency overdose situations, providing a safer and more accessible solution for at-risk individuals and first responders." The ongoing opioid epidemic, largely driven by fentanyl and other synthetic opioids, has led to a dramatic rise in overdose fatalities worldwide. Naloxone, an FDA-approved opioid antagonist, has been shown to reverse opioid toxicity when administered promptly after respiratory depression occurs. The global Naloxone market is projected to reach $2.47 billion by 2032, growing at a CAGR of 11%. The Naloxone intranasal spray market alone is expected to reach $1.4 billion by 2030 (Vantage Market Research, February 2022). Intranasal delivery of Naloxone presents several advantages, including ease of administration, eliminating the need for trained medical personnel, reduced risk of needlestick injuries and increased accessibility, allowing emergency responders, caregivers, and at-risk individuals to carry and use it effectively. About Polyrizon Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon's proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a "biological mask" with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please visit https://polyrizon-biotech.com. Forward Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its belief that its Trap and Target™ (T&T) platform holds the potential to enhance intranasal Naloxone by offering higher bioavailability for increased drug effectiveness and optimized drug release profiles that ensure rapid opioid reversal. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission ("SEC"), including, but not limited to, the risks detailed in the Company's prospectus (Registration No. 333-266745), dated October 24, 2024 and filed with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites. Contacts: Michal Efraty Investor Relations IR@polyrizon-biotech.com

100 Deals associated with Fentanyl

External Link

KEGG	Wiki	ATC	Drug Bank
D00320	Fentanyl	N02AB03 N01AH01	DB00813

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cancer Pain	Japan	Janssen Pharmaceutical KK	01 Feb 2011
Pain	Australia	Janssen-Cilag Pty Ltd.	23 Nov 2005
Acute Pain	United States	Janssen Pharmaceuticals, Inc.	04 Feb 2005
Chronic Pain	United States	Janssen Pharmaceuticals, Inc.	04 Feb 2005
Hypoventilation	United States	Janssen Pharmaceuticals, Inc.	07 Aug 1990
Pain, Postoperative	United States	Janssen Pharmaceuticals, Inc.	07 Aug 1990

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Mucositis	Phase 3	United States	INSYS Therapeutics, Inc.	01 Oct 2009
Solid tumor	Phase 3	United States	INSYS Therapeutics, Inc.	01 Oct 2009
Stomatitis	Phase 3	United States	INSYS Therapeutics, Inc.	01 Oct 2009
Low Back Pain	Phase 3	Japan	Janssen Pharmaceuticals, Inc.	01 Jan 2009
Osteoarthritis	Phase 3	Japan	Janssen Pharmaceuticals, Inc.	01 Jan 2009
Complex Regional Pain Syndromes	Phase 3	Japan	Janssen Pharmaceuticals, Inc.	01 Dec 2008
Neuralgia, Postherpetic	Phase 3	Japan	Janssen Pharmaceuticals, Inc.	01 Dec 2008
Pain Disorder	Phase 3	Japan	Janssen Pharmaceuticals, Inc.	01 Dec 2008
Pain, Intractable	Phase 3	-	Janssen Pharmaceuticals, Inc.	01 May 2005
Neoplasms	Phase 3	-	ALZA Corp.	01 May 1986

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04230681 (CTgov)	Early Phase 1	Sleep Apnea, Obstructive \| Tonsillitis	189	Hydromorphone (Hydromorphone)	xyzsbuoexr = yrgxyvzxas fhrajxvcyj (wcubqmhztl, fwfmueyqcp - coxtceabyx) View more	-	18 Dec 2024
				Fentanyl (Fentanyl)	xyzsbuoexr = eopnwmcoyk fhrajxvcyj (wcubqmhztl, hiwkqlycob - qhhhrlkuhf) View more
ASH2024	Not Applicable	Acute Pain \| Anemia, Sickle Cell	-	Intranasal Fentanyl (INF)	jwocuzsyau(zgvrynuaex) = 7 (18%) of visits ewmpynxsfn (rsfobrrdcc ) View more	-	08 Dec 2024
NCT05244226 (CTgov)	Phase 2	Sleep Apnea, Obstructive \| Tonsillitis \| Pain, Procedural	66	Hydromorphone+Fentanyl	evrghnqesh(epnkpsnzrj) = cftayncchw hjiibgnlbp (amsiprzcyx, dbbhtlnvim - sdimpjbcxh) View more	-	17 Oct 2024
SFN2023	Not Applicable	Opioid abuse \| Respiratory Insufficiency	-	Fentanyl + Xylazine + Oxytocin	esguhdcvxa(nnwxstzifn) = gkvrbrfqod udafxfxtej (jkkyspbbxq )	-	12 Nov 2023
NCT03115151 (CTgov)	Phase 4	Pain	46	Fentanyl+Bupivacaine (Patient-Controlled Epidural Analgesia)	juhwozpdlf(cbejxugypb) = jltwpcmpmn bgahafiifs (lrvpbjmlqf, 24.69) View more	-	26 Oct 2023
				Hydromorphone (Intravenous Patient-controlled Analgesia)	juhwozpdlf(cbejxugypb) = ztqzvafpce bgahafiifs (lrvpbjmlqf, 25.41) View more
ICML2023	Not Applicable	18 FDG	-	Fentanyl pre-treatment	xetkdkxueq(vuvahajrzd) = wruejmrtad cdabueyqge (ylhbwcnsfm )	Positive	09 Jun 2023
				No fentanyl pre-treatment	xetkdkxueq(vuvahajrzd) = xnzsvefncj cdabueyqge (ylhbwcnsfm )
P12-11.015 (AAN2023)	Not Applicable	Parkinson Disease	1,581	Fentanyl patch	dgyapdiazb(vxlyjrlzdr) = involuntary, nonsuppressible writhing motion of the face, trunk and all limbs rvewenohxp (zvumdrwpww ) View more	Negative	25 Apr 2023
Pubmed \| Braz J Anesthesiol	Not Applicable	Anesthesia	-	Spinal fentanyl	woymnxsdse(qspxmcthdr) = nmlqltzjkm bmjhvtinot (rsgdpyhzdj )	-	01 Mar 2023
				Spinal sufentanil	woymnxsdse(qspxmcthdr) = ngqndwtibz bmjhvtinot (rsgdpyhzdj )
NCT00580489 (CTgov)	Not Applicable	Pain \| Drug-Related Side Effects and Adverse Reactions	204	fentanyl+morphine (Arm C Morphine)	fzgeutriwp = oneobzvkcz ofeqphnexf (jzfoolivpj, huidhvpjns - geadsqyfkd)	-	16 Aug 2022
				fentanyl+morphine (Arm D Fentanyl)	fzgeutriwp = cuqtdmmgsr ofeqphnexf (jzfoolivpj, ecgtlyynnp - rmllqbfrby)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis